Hitting the Bullseye in NSCLC:
Updates on EGFR-Targeting Therapies

Lung cancer is the second most common cancer in both men and women and is the leading cause of cancer-related deaths. The majority of lung cancer cases are categorized as NSCLC, which has a low overall 5-year survival rate, especially when it is diagnosed at advanced, unresectable stages. Recent advances in the treatment landscape have yielded promising improvements in progression-free survival and overall survival; however, outcomes are dependent on numerous factors, including the evaluation of mutational status and prompt implementation of targeted therapeutic strategies. This 4-part CME Snapshot activity has been designed to educate and promote critical thinking through a discussion-based format, with elements of 3D animation. Multidisciplinary expert faculty discuss the appropriate molecular testing techniques to evaluate mutational status and provide practical recommendations for individualized treatment strategies in unresectable EGFR+ NSCLC based on their clinical experience and the latest published clinical evidence.